Virchow JC, McDonald M, Garin M, Korn S. Reslizumab as Add-on Therapy in Patients With Refractory Asthma. BMJ Open Resp Res 2020

Panettieri RA, Welte T, Shenoy KV, Korn S, Jandl M, Kerwin EM, Feijoo R, Barker P, Olsson RF, Martin UJ. Onset of Effect, Changes in Airflow Obstruction and Lung Volume, and Health-Related Quality of Life Improvements with Benralizumab for Patients with Severe Eosinophilic Asthma: Phase IIIb Randomized, Controlled Trial (SOLANA). Journal of Asthma and Allergy 2020

Milger K, Korn S, Buhl R, Hamelmann E, Herth F, Gappa M, Drick N, Fuge J, Suhling H. Age- and sex-dependent differences in patients with severe asthma included in the German Asthma Net cohort. Resp Med 2020 Feb 162:105858

Korn S, Buhl R. Reply to the Letter Entitled "FeNO Variability when Using Different Analyzers at the Joint ATS/ERS Guideline Cutoff". Respiration. 2020;99(1):94

van Bragt JJMH, Adcock IM, Bel EHD, Braunstahl GJ, Ten Brinke A, Busby J, Canonica GW, Cao H, Chung KF, Csoma Z, Dahlén B, Davin E, Hansen S, Heffler E, Horvath I, Korn S, Kots M, Kuna P, Kwon N, Louis R, Plaza V, Porsbjerg C, Ramos-Barbon D, Richards LB, Škrgat S, Sont JK, Vijverberg SJH, Weersink EJM, Yasinska V, Wagers SS, Djukanovic R, Maitland-van der Zee AH. Characteristics and treatment regimens across ERS SHARP severe asthma registries. Eur Respir J. 2020 Jan 9;55(1).

Buhl R, Korn S, Menzies-Gow A, Aubier M, Chapman KR, Canonica GW, Picado C, Donica M, Kuhlbusch K, Korom S, Hanania NA. A prospective, single-arm, longitudinal cohort study to assess biomarkers in real-world patients with severe asthma (ARIETTA). JACI: In Practice 2020

Korn S, Wilk M, Voigt S, Weber S, Keller T, Buhl R. Measurement of fractional exhaled nitric oxide (FeNO): comparison of three different analysers. Respiration. 2020;99(1):1-8

Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, Pricek RG, Humbert M. Long-Term Safety and Clinical Benefit of Mepolizumab in Patients with the Most Severe Eosinophilic Asthma: The COSMEX Study . Clin Ther. 2019 Oct;41(10):2041-2056

Busse WW, Brusselle GG, Korn S, Kuna P, Magnan A, Cohen D, Bowen K, Piechowiak T, Wang MM, Colice G. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. Eur Respir J. 2019 Jan 31;53(2)

Weinstein SF, Katial RK, Bardin P, Korn S, McDonald M, Garin M, Bateman ED, Hoyte FCL, Germinaro M. Effects of Reslizumab on Asthma Outcomes in a Subgroup of Eosinophilic Asthma Patients with Self-Reported Chronic Rhinosinusitis with Nasal Polyps. J Allergy Clin Immunol Pract. 2019 Feb;7(2):589-596

Djukanovic R, Adcock IM, Anderson G, Bel EH, Canonica GW, Cao H, Chung KF, Davies DE, Genton C, Gibson-Latimer T, Hamerlijnck D, Heuvelin E, Louis R, Korn S, Kots M, Kwon N, Naddaf R, Wagers SS. The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research. Eur Respir J. 2018 Nov 29;52(5)

Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, Martinot JB, Sagara H, Albers FC, Bradford ES, Harris SS, Mayer B, Rubin DB, Yancey SW, Sciurba FC. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017 Oct 26;377(17):1613-1629

Buhl R, Bals R, Baur X, Berdel D, Criée CP, Gappa M, Gillissen A, Greulich T, Haidl P, Hamelmann E, Kardos P, Kenn K, Klimek L, Korn S, Lommatzsch M, Magnussen H, Nicolai T, Nowak D, Pfaar O, Rabe KF, Riedler J, Ritz T, Schultz K, Schuster A, Spindler T, Taube C, Taube K, Vogelmeier C, von Leupoldt A, Wantke F, Weise S, Wildhaber J, Worth H, Zacharasiewicz A. [Guideline for the Diagnosis and Treatment of Asthma - Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology]. Pneumologie. 2017 Dec;71(12):849-919

Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, Heinrich J, Schulz H, Gläser S, Holle R, Watz H, Korn S, Adaskina N, Biertz F, Vogel C, Vestbo J, Wouters EF, Rabe KF, Söhler S, Koch A, Jörres RA; COSYCONET Study Group. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016 May;114:27-37

Meyer-Martin H, Hahn SA, Beckert H, Belz C, Heinz A, Jonuleit H, Becker C, Taube C, Korn S, Buhl R, Reuter S, Tuettenberg A. GARP inhibits allergic airway inflammation in a humanized mouse model. Allergy. 2016 Sep;71(9):1274-83

Buhl R, Korn S, Menzies-Gow A, Aubier M, Chapman KR, Canonica GW, Picado C, Martin N, Escobar RA, Korom S, Hanania NA. Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 Jun;115:7-12

FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, Gilmartin G, Werkström V, Aurivillius M, Goldman M; CALIMA study investigators. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Sep 5. pii: S0140-6736(16)31322-8. doi: 10.1016/S0140-6736(16)31322-8

Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, May RD, Streicher K, Ranade K, Piper E. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med. 2015 Sep;3(9):692-701

Ferguson GT, Flezar M, Korn S, Korducki L, Grönke L, Abrahams R, and Buhl R. Efficacy of Tiotropium + Olodaterol in Patients with COPD by Initial Disease Severity and Treatment Intensity. Advances in Therapy, 2015 Jun;32(6):523-36

Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, and Renz H. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N Engl J Med. 2015 May 21;372(21):1987-95

Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O'Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015 May;3(5):355-66

Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, Korn S. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax. 2015 Apr;70(4):311-9

Singh D, Jones PW, Bateman ED, Korn S, Serra C, Molins E, Caracta C, Gil EG, and Leselbaum A. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med. 2014 Nov 18;14:178

K. M. Beeh, S. Korn, J. Beier, D. Jadayel, M. Henley, P. D'Andrea, and D. Banerji. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014 108 (4):584-592

Beeh KM, Moroni-Zentgraf P, Ablinger O, Hollaenderova Z, Unseld A, Engel M, Korn S. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma. Respir Res 15 (1):61, 2014

Schreiber J, Kopp MV, Korn S, Taube C, Buhl R. [Disease Modification and Duration of Omalizumab Treatment in Patients with Severe Allergic Asthma.]. Pneumologie, 2014

Lommatzsch M, Korn S, Buhl R, Virchow JC. Against all odds: anti-IgE for intrinsic asthma? Thorax 69(1):94-6, 2014
Korn S, Hübner M, Jung M, Blettner M, Buhl R. Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency. Respir Res 22;14(1):25, 2013

Pavord I, Korn S, Howarth P, Bleecker G, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab (anti-IL-5) reduces exacerbations in patients with refractory eosinophilic asthma. Lancet. 18;380(9842):651-9, 2012;

Decramer M, Dahl R, Kornmann O, Korn S, Lawrence D, McBryan D. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use. Respir Med. 2012;

Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med. 106(11):1494-500, 2012

C. Bachert, Steen K. Van, N. Zhang, G. Holtappels, T. Cattaert, B. Maus, R. Buhl, C. Taube, S. Korn, M. Kowalski, J. Bousquet, and P. Howarth. Specific IgE against Staphylococcus aureus enterotoxins: An independent risk factor for asthma. J Allergy Clin Immunol. 130 (2):376-381, 2012.

Strohner P, Korn S, Buhl R, Becher G. The Recovery-ELISA – a novel assay technique for monitoring the therapy with humanized antibodies using the example of omalizumab. Journal of Immunoassay and Immunochemistry. 2012; DOI: 10.1080/15321819.2012.683501

Martin H, Reuter S, Dehzad N, Heinz A, Bellinghausen I, Saloga J, Haasler I, Korn S, Jonuleit H, Buhl R, Becker C, Taube C. CD4-mediated regulatory T-cell activation inhibits the development of disease in a humanized mouse model of allergic airway disease. J Allergy Clin Immunol. 2011; 129(2):521-8

Korn S, Buhl R. Comparison of the Efficacy of a Fixed Combination of Ciclesonide and Formoterol versus a Fixed Combination of Fluticasone and Salmeterol. The EXCITED-study. Respir Med. 2012; 106 (1):57-67

Korn S, Kerwin E, Atis S, Amos C, Owen R, Lassen C. INSIST Study Group. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study. Respir Med. 2011; 105(5):719-26

Korn S, Both J, Jung M, Hubner M, Taube C, Buhl R. Prospective evaluation of current asthma control using ACQ and ACT compared with GINA criteria. Ann Allergy Asthma Immunol. 2011; 107 (6):474-79

Taube C, Rydzy L, Eich A, Korn S, Kornmann O, Sebastian M, Jorres RA, Buhl R. Use of a portable device to record maximum inspiratory flow in relation to dyspnoea in patients with COPD. Respir Med. 2010; 105(2):316-21

Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, Buhl R. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol. 2010; 105 (4):313-9

Korn S, Telke I, Kornmann O, Buhl R. Measurement of exhaled nitric oxide: comparison of different techniques. Respirology. 2010; 15 (8):1203-8

Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med. 2009; 103:1725-31 (Impact factor 3.237; Habilitationswert B)

Meyer R*, Korn S*, Becker K, Buhl R. An open-Label, Prospective Phase I/II Study Evaluating the Immunogenicity and Safety of EMD 249 590 (RAS Peptide Vaccine) plus GM-CSF in Patients with Non-Small Cell Lung Cancer. Lung Cancer. 2007; 58:88-94
*both authors contribute equally

Korn S, Beier J, Kornmann O, Heilmann C, Buhl R, Beeh KM. Discrepant nasal and bronchial nitric oxide kinetics during early and late phase allergic reactions. Respir Med. 2005; 99(12):1595-99

Korn S, Wiewrodt R, Walz YC, Becker K, Mayer E, Krummenauer F, Buhl R. Characterization of the interstitial lung and peripheral blood T cell receptor repertoire in smokers. Am J Respir Cell Mol Biol. 2005; 32 (2):142-148

Drick N, Milger K, Seeliger B, Fuge J, Korn S, Buhl R, Schuhmann M, Herth F, Kendziora B, Behr J, Kneidinger N, Bergmann KC, Taube C, Welte T, Suhling H. Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma. J Asthma Allergy. 2020 Nov 11;13:605-614. (Impact factor 3.730)

Buhl R, Dreher M, Korn S, Taube C, Stock C, Zehendner CM, Kondla A, Vogelmeier CF. A Non-Interventional Study of Tiotropium/Olodaterol versus Any Triple Combination Therapy for Chronic Obstructive Pulmonary Disease: The EVELUT® Study Protocol. Int J Chron Obstruct Pulmon Dis. 2020 Oct 22;15:2601-2608.

Buhl R, Korn S, Menzies-Gow A, Aubier M, Chapman KR, Canonica GW, Picado C, Donica M, Kuhlbusch K, Korom S, Hanania NA. Prospective, Single-Arm, Longitudinal Study of Biomarkers in Real-World Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2020 Sep;8(8):2630-2639.e6. doi: 10.1016/j.jaip.2020.03.038.